Nebivolol and incident cardiovascular events in hypertensive patients compared with nonvasodilatory beta blockers

Arterial Stiffness and Cardiovascular Risk in Hypertension

(2021) Pierre Boutouyrie et al.   CIRCULATION RESEARCH

Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients

(2021) Seng Chan You et al.   HYPERTENSION

2020 International Society of Hypertension Global Hypertension Practice Guidelines

(2020) Thomas Unger et al.   HYPERTENSION

Effect of Nebivolol and Olmesartan on 24-Hour Brachial and Aortic Blood Pressure in the Acute Stage of Ischemic Stroke

(2019) Eleni Georgianou et al.   International Journal of Hypertension

2018 ESC/ESH Guidelines for the management of arterial hypertension

(2018) Bryan Williams et al.   EUROPEAN HEART JOURNAL

Global Risk Assessment to Guide Blood Pressure Management in Cardiovascular Disease Prevention

(2017) Kunal N. Karmali et al.   HYPERTENSION

Nebivolol, But Not Metoprolol, Treatment Improves Endothelial Fibrinolytic Capacity in Adults With Elevated Blood Pressure

(2017) Brian L. Stauffer et al.   Journal of the American Heart Association

Chronic Nebivolol Treatment Suppresses Endothelin-1–Mediated Vasoconstrictor Tone in Adults With Elevated Blood PressureNovelty and Significance

(2016) Kyle J. Diehl et al.   HYPERTENSION

Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis

(2016) Dena Ettehad et al.   LANCET

A Review of Nebivolol Pharmacology and Clinical Evidence

(2015) Justin Fongemie et al.   DRUGS

Effects of blood pressure lowering on outcome incidence in hypertension

(2015) Costas Thomopoulos et al.   JOURNAL OF HYPERTENSION

Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data

(2014)   LANCET

Differential Effects of Nebivolol and Metoprolol on Central Aortic Pressure and Left Ventricular Wall Thickness

(2011) Priit Kampus et al.   HYPERTENSION